010-84476011
环球医学>> 医学新闻>> 肿瘤>>正文内容
肿瘤

Afinitor获欧盟批准治疗乳腺癌

来源:环球医学编译    时间:2012年07月31日    点击数:    5星

7月31日消息--环球医学据悉,诺华公司说,在六月获得专家小组支持后,欧洲监管机构于本周一批准了Afinitor治疗妇女某一类型的乳腺癌。

Afinitor是批准用于治疗绝经后妇女激素受体阳性及HER-2阴性恶性乳腺癌的第一种mTOR抑制剂。美国卫生监管部门也支持此药物用于治疗乳腺癌(编号:nL2E8IKD8B)。

Afinitor也称依维莫司,旨在与另一种药物阿诺新联合给药,治疗那些在接受其他两种治疗后癌症复发或者病情恶化的妇女。阿诺新由辉瑞公司生产。

诺华(有望成为瑞士制药商的主要卖方)的药物已经被批准用于治疗四种其他类型癌症的患者(包括肾癌及罕见类型的胰腺癌)。(环球医学)

原文

Novartis drug Afinitor wins EU nod to treat breast cancer

(Reuters) - Novartis said on Monday European regulators approved Afinitor to treat women with a certain type of breast cancer, following a panel backing in June.

The drug is the first in a class known as mTOR inhibitors to be approved for post-menopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. American health regulators also backed the drug as a breast cancer treatment[ID:nL2E8IKD8B]

Afinitor, also known as everolimus, is designed to be given in combination with another drug, Aromasin, to treat women whose cancer has recurred or progressed after treatment with two other therapies. Aromasin is made by Pfizer Inc.

Novartis's drug - expected to become a major seller for the Swiss drugmaker - is already approved to treat patients with four other types of cancer, including kidney and a rare type of pancreatic cancer.

 

         相关链接:http://www.reuters.com/article/2012/07/30/us-novartis-idUSBRE86T03320120730

版权声明:本文系环球医学独家稿件,版权为环球医学所有。欢迎转载,请务必注明出处(环球医学网),否则必将追究法律责任。

 

 

 


 

评价此内容
 我要打分

现在注册

联系我们

最新会议

    [err:标签'新首页会议列表标签'查询数据库时出现异常。有关错误的完整说明,请到后台日志管理中查看“异常记录”]